GLA and Fabry disease: In 2001, the introduction of two enzyme replacement therapies (ERTs) administered intravenously every other week, agalsidase alfa (0.2 mg/kg body weight) [13] and agalsidase beta (1 mg/kg body weight) [14, 15], provided the first opportunity to address the underlying α-Gal A deficiency and associated clinical FD sequelae.